Bristol-Myers Squibb appoints James Palmer as chief scientific officer
Bristol-Myers Squibb Company has named Dr James B. D. Palmer to succeed Dr Peter Ringrose as chief scientific officer responsible for the company's worldwide pharmaceutical r&d operations. His appointment is effective 1 December. Dr. Palmer joins the company from GlaxoSmithKline, where he was senior vice president for new product development and brings more than 17 years of scientific and product development experience to his new position.
'Dr Palmer's r&d acumen and commercial orientation will be a great asset as we continue to manage our development portfolio,' said Peter R. Dolan, chairman and ceo for B-MS. 'He is a seasoned r&d executive with strong expertise in regulatory interactions with the US FDA and other global regulators. He has an outstanding record of successful product filings and approvals in a range of therapeutic areas and is well-prepared to lead our worldwide research and development efforts.'